Finally, with the existence of an FDA-approved GHR antagonist and several others in active development targeting the full spectrum of GH action [28,67,80], our current study sets course in a feasible paradigm shift in the therapeutic augmentation of pancreatic cancer. The gene discussed is GHR; the disease is pancreatic neoplasm.